Treating ALS with stem cell injections: A clinical trial
Dr. Eva Feldman, a neurologist, researcher and director of the A. Alfred Taubman Biomedical Research Institute at the University of Michigan, is the principal investigator for a landmark clinical trial involving patients with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. The FDA-approved trial, which currently is in the safety phase, involves injecting hundreds of thousands of stem cells into the spinal cords of patients with ALS. As Dr. Feldman explains in this video, it is hoped that the stem cells will provide a healthier environment for the patients' own nerve cells, preserving function and improving quality of life.
Dr. Eva Feldman: Alfred Taubman as mentor, leader, friend
The source of his greatness lay in his willingness to challenge conventional thinking.
Emerging Scholars Symposium set for April 29
Annual showcase of early career physician-researchers runs 10 a.m. to noon at the A. Alfred Taubman Biomedical Science Research Building.
Dr. Max Wicha receives $6.5 million to target cancer stem cells
The award from the National Cancer Institute will fuel research into the cells that cause metastasis.
news & events
In the News
Taubman Emerging Scholar partners in ACL repair study
Asheesh Bedi, M.D., is an investigator in a study using human growth hormone to aid healing of the common knee injury.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D. and team find a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Arthritis drug may help diabetics with kidney disease
Research led by Taubman Scholar Frank Brosius has led to a fast-track study that shows promising results